Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | DHODH | Q02127 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12296366 | 0.82 | MAPT (0.79) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL2885791 | 0.82 | MAPT (1.00) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL27706920 | 0.80 | RAB9A (0.80) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL12158128 | 0.80 | MAPT (0.71) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL4926010 | 0.80 | RAB9A (0.62) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL3606993 | 0.79 | KMT2A (0.54) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL4765972 | 0.79 | NPC1 (0.76) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL4916014 | 0.78 | MAPT (0.52) | MAPTRAB9ANPC1HPGDKDM4E | |
| SCHEMBL14073914 | 0.77 | CDK5 (0.73) | MAPTRAB9ANPC1DHODHLMNA | |
| SCHEMBL7107744 | 0.77 | CDC25B (0.69) | MAPTRAB9ANPC1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | KCNA5, KCNA1, KCNJ2 | MAPT 1729/4885RAB9A 1327/4885NPC1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.